We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01055756
Recruitment Status : Withdrawn
First Posted : January 26, 2010
Last Update Posted : October 31, 2022
Sponsor:
Information provided by (Responsible Party):
Azidus Brasil

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary objective of this study is to evaluate the clinical efficacy of the drug Cloratadd D ® (loratadine + pseudoephedrine sulfate - EMS S/A) compared to the drug Claritin D ® (loratadine + pseudoephedrine sulfate - Schering Plough) in patients with allergic rhinitis by quantification of the scores of clinical parameters (signs and symptoms) and laboratory (nasal flow) down through time.

Condition or disease Intervention/treatment Phase
Allergic Rhinitis Drug: Loratadine + Pseudoephedrine sulfate Phase 3

Detailed Description:
Secondly, it will be observed safety (tolerability) clinic after the administration of the drug in patients by comparing the clinical parameters and the incidence of adverse events.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : January 2010
Estimated Primary Completion Date : April 2010
Estimated Study Completion Date : June 2010

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Test (Cloratadd D)
Loratadine + Pseudoephedrine sulfate Test
 Drug: Loratadine + Pseudoephedrine sulfate
Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)
Active Comparator: Comparator (Claritin D)
Loratadine + Pseudoephedrine Comparator
 Drug: Loratadine + Pseudoephedrine sulfate
Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Clinical signs and symptoms and nasal flow [ Time Frame: 12 hours. ]

Secondary Outcome Measures :
  1. Avaliation of Safety through the adverse affects observation [ Time Frame: 12 hours ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Accept the Consent Form.
  2. Age between 18 and 60 years, regardless of sex;
  3. Agree to return to all evaluations of the study;
  4. Presenting the allergic symptoms confirmed by physical examination and by laboratory tests (IgE and sensitivity to the mite Dermatophagoides pteronyssinus), which should provide a diagnosis of allergic rhinitis with mild to moderate.

Exclusion Criteria:

  1. Have participated in any experimental study or have ingested any drug trial in the 12 months preceding the start of the study;
  2. Made use of other medications that interfere with the regular response of the drug in the 4 weeks preceding the start of the study, such as steroids and antihistamines;
  3. Be patient with sensitivity loratadine / pseudoephedrine sulfate;
  4. Have any disease or anatomical abnormality in the upper airways is detrimental to the analysis of data, for example, tumors or septal deviations moderate and severe
  5. Demonstrate a history of alcohol abuse, drugs or pharmaceuticals.
  6. Have consumed alcohol within 48 hours prior to the period of hospitalization;
  7. Have a history of liver disease or kidney disease;
  8. Present framework of current asthma or recent (less than 1 year);
  9. To present the severe pressure of any cause or be on medication for that;
  10. Smokers or patients who stopped smoking less than 06 months;
  11. Pregnant or nursing women;
  12. Patients with heart disease or who use medication for the cardiovascular system that is suffering interference of the drugs studied, for example, β-blockers;
  13. Patients using corticosteroids or other medicines that interact with the study drugs as monoamine oxidase;
  14. Patients with a history of glaucoma, urinary retention, and hyperthyroidism;
  15. Patients who have undergone facial plastic surgery that the physician's discretion, will interfere with nasal airflow
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01055756


Locations
Layout table for location information
Brazil
LAL Clínica Pesquisa e Desenvolvimento Ltda
Valinhos, São Paulo, Brazil, 13276245
Sponsors and Collaborators
Azidus Brasil
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Azidus Brasil
ClinicalTrials.gov Identifier: NCT01055756    
Other Study ID Numbers: LOREMS0909
Version 3, Amendment 1
First Posted: January 26, 2010    Key Record Dates
Last Update Posted: October 31, 2022
Last Verified: October 2022
Keywords provided by Azidus Brasil:
Reduction of signs and symptoms and enhanced nasal flow
Nasal Flow
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis
Rhinitis, Allergic
Respiratory Tract Infections
Infections
Nose Diseases
Respiratory Tract Diseases
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Loratadine
Pseudoephedrine
Ephedrine
Antipruritics
 Dermatologic Agents
Anti-Allergic Agents
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Nasal Decongestants